Friday, April 17, 2015

Antibe testing confirms ATB-346 efficacy at lower doses

2015-04-17 07:50 ET - News Release

Mr. Dan Legault reports
Antibe Therapeutics Inc. released today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346.

The results support the company's earlier communication that ATB-346 may be effective at much lower doses than previously expected and that once-daily dosing may be effective. Together, over 600 blood samples from its phase 1 human clinical trial were independently analyzed to assess the ability of ATB-346, at doses ranging from 25 milligrams to 1,000 milligrams, to inhibit the enzyme cyclooxygenase (COX). The reduction of pain and inflammation by non-steroidal anti-inflammatory drugs is attributed to their ability to inhibit COX activity.

Substantial inhibition of COX was observed at doses of ATB-346 as low as 75 milligrams, and the inhibition was maintained for 24 hours. The company continues to conduct validation studies and will report to the market as they proceed.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.